At the heart of today’s health industry challenges

Today, as a result of a rise in antibiotic resistance, infectious diseases represent a major challenge for public health and are listed as the No.1 priority by the World Health Organization. In this context, Vivexia specialized in evaluating the efficacy of anti-infective drugs in living humanized models.

For more than 10 years, we have been providing a wide range of in vivo and in vitro models that can be applied to the development of anti-infective treatments for use by public health laboratories, healthcare facilities, TPE, SME and large companies within the pharmaceutics industry with which we enjoy a close collaboration.

Savoir-faire

In vivo models

Vivexia’s mission is to offer evaluation models that are as predictive as possible of the potential of your therapeutic innovations. In addition, we have developed and validated more than thirty pathological infection models.


See more

In vitro services

Vivexia has developed an expertise in microbiology that allows us to offer a whole range of support services for the in vitro evaluation (susceptibility / resistance) of your anti-infective molecules, whatever their nature.


See more

Publications

July 2020
In vivo efficacy of a combination of therapeutic bacteriophages in a mouse
In vivo efficacy of a combination of therapeutic bacteriophages in a mouse model of S. aureus Diabetic Foot Ulcer (DFU) infection
March 2019
Preventing lung pathology and mortality in rabbit Staphylococcus aureus pneumonia models
Preventing lung pathology and mortality in rabbit Staphylococcus aureus pneumonia models with cytotoxin-neutralizing monoclonal IgGs penetrating the epithelial lining fluid

News

December 2019
Vivexia was present at RICAI 2019
www.ricai.fr